Eduardo Marban, Cedars-Sinai Heart Institute - Keynote at 9th Stem Cell Event (Oct 24-26, 2012, PA)
Eduardo Marban, Director & Mark S. Siegel Family Professor of Cedars-Sinai Heart Institute to give a Keynote Presentation at the 9th Stem Cell Research & Therapeutics Conference (Oct 24-26, 2012 in Philadelphia, PA).
- San Francisco, CA (1888PressRelease) August 09, 2012 - Eduardo Marban, Director & Mark S. Siegel Family Professor of Cedars-Sinai Heart Institute to give a Keynote Presentation on "Therapeutic Regeneration of the Injured Human Heart" at the 9th Stem Cell Research & Therapeutics Conference (Oct 24-26, 2012 in Philadelphia, PA)
Cardiosphere-derived cells (CDCs) have been shown to reduce infarct scar, increase viable myocardium and boost regional heart function in the randomized controlled CADUCEUS (CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction) trial (R. Makkar et al., Lancet 379:895-904, 2012).
This is the first therapeutic modality, targeted at any organ, shown to reverse injury while simultaneously re-growing healthy tissue. This talk will cover the following points:
- Evidence for therapeutic regeneration in CADUCEUS
- Validation studies
- Mechanisms of regeneration
- Surrogate endpoints in clinical trials: which ones are best?
- Future clinical studies using CDCs
Eduardo Marbán, MD, PhD, the director of the Cedars-Sinai Heart Institute, is an international leader in cardiology and a pioneering heart researcher. His 20-plus years of patient care as well as his research into how the heart works on the molecular and cellular levels, and how heart disease progresses, have led to key discoveries in gene and stem cell therapies and new drug treatments for heart attacks, heart failure and strokes. Those discoveries resulted in inventions and patents that have formed the basis for three startup companies. Dr. Marbán also directs Cedars-Sinai's Board of Governors Heart Stem Cell Center, which is focused on cardiac regeneration.
Using techniques that he has pioneered to isolate stem cells from a patient's own heart, Dr. Marbán has completed the first-in-human NIH-funded CADUCEUS trial. The study was the first to show that cell therapy can repair "irreversible" tissue damage caused by heart attacks.
GTC's 9th Stem Cell Research & Therapeutics Conference, taking place on October 24-26, 2012 in Philadelphia, PA forum presents information novel advances and technologies, advanced pre-clinical disease modes, overcoming challenges in clinical development, commercialization, distribution and manufacturing, and a panel discussion on the best uses of iPS & hESC sourced pluripotent cells.
Presenting will be Top Executive Speakers from the following Companies: Osiris, ATRM, a Johnson & Johnson Company, Angiocrine Bioscience, Athersys, Bioheart, Capricor, Celgene, Cellectis Stem Cells, Eli Lilly, Genentech, GlaxoSmithKline, Janssen, NIH, Pfizer, Pluristem, Regenerative Patch Technologies, Roche, SanBio, Tengion, and many more!
To view the Program Agenda Click Here. To view the Speaker List Click Here.
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam